W Weng1, Y Liang2, E Kimball3, T Hobbs3, S Kong3. 1. Novo Nordisk Inc., Plainsboro, NJ, USA. Electronic address: wayw@novonordisk.com. 2. Novo Nordisk Inc., Plainsboro, NJ, USA; Truven Health Analytics, Cambridge, MA, USA. 3. Novo Nordisk Inc., Plainsboro, NJ, USA.
Abstract
AIMS: To gather real-world data on treatment characteristics and comorbidity progression in patients with newly-diagnosed type 2 diabetes (T2D) and evaluate differences by patient age. METHODS: Retrospective analysis of a US administrative claims database including 16,950 subjects with newly-diagnosed T2D in 2006 and a baseline Diabetes Complications Severity Index (DCSI) score of 0. Patients were categorized by DCSI score at year 8 (0, 1-2, or ≥3) and comparatively analyzed based on demographic variables, drug usage, and diabetes-related comorbidities. RESULTS: Year 8 DCSI score distribution was 0 (29.9%), 1-2 (36.2%), and ≥3 (33.9%). The highest DCSI score subgroup (≥3) was characterized by a significantly greater percentage of males, older age at T2D diagnosis, and higher Medicare enrollment. DCSI progressed most rapidly in the oldest age group (≥65). Among all subjects at year 8, insulin use was significantly highest among subjects with DCSI ≥3 compared with those having a lower DCSI. However, for subjects with DCSI ≥3, insulin use was lower among those in the oldest age group (≥65) relative to younger age groups. CONCLUSIONS: These real-world data suggest a relationship between age at T2D diagnosis and disease progression based on comorbidity burden and lower usage of injectable therapies in older patients.
AIMS: To gather real-world data on treatment characteristics and comorbidity progression in patients with newly-diagnosed type 2 diabetes (T2D) and evaluate differences by patient age. METHODS: Retrospective analysis of a US administrative claims database including 16,950 subjects with newly-diagnosed T2D in 2006 and a baseline Diabetes Complications Severity Index (DCSI) score of 0. Patients were categorized by DCSI score at year 8 (0, 1-2, or ≥3) and comparatively analyzed based on demographic variables, drug usage, and diabetes-related comorbidities. RESULTS: Year 8 DCSI score distribution was 0 (29.9%), 1-2 (36.2%), and ≥3 (33.9%). The highest DCSI score subgroup (≥3) was characterized by a significantly greater percentage of males, older age at T2D diagnosis, and higher Medicare enrollment. DCSI progressed most rapidly in the oldest age group (≥65). Among all subjects at year 8, insulin use was significantly highest among subjects with DCSI ≥3 compared with those having a lower DCSI. However, for subjects with DCSI ≥3, insulin use was lower among those in the oldest age group (≥65) relative to younger age groups. CONCLUSIONS: These real-world data suggest a relationship between age at T2D diagnosis and disease progression based on comorbidity burden and lower usage of injectable therapies in older patients.
Authors: Mohammad E Yadegarfar; Chris P Gale; Tatendashe B Dondo; Chris G Wilkinson; Martin R Cowie; Marlous Hall Journal: BMC Med Date: 2020-08-24 Impact factor: 8.775
Authors: David R Matthews; Carol Wysham; Melanie Davies; April Slee; Maria Alba; Mary Lee; Vlado Perkovic; Kenneth W Mahaffey; Bruce Neal Journal: Diabetes Obes Metab Date: 2020-08-24 Impact factor: 6.577